AI assistant
DEXCOM INC — Director's Dealing 2021
Nov 11, 2021
30198_dirs_2021-11-10_e87f91ea-9b68-4573-be72-e91ea4ae50d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-11-09
Reporting Person: Sylvain Jereme M (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-09 | Common Stock | A | 634 | $634.12 | Disposed | 12892 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 9,759 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.